Weil Serves as Antitrust Counsel to Abbott in its ~$21 Billion Acquisition of Exact Sciences

Abbott Laboratories, a global leader in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals, has engaged Weil as antitrust counsel in connection with its roughly $21 billion acquisition of Exact Sciences. Weil provides strategic guidance on antitrust review and-related regulatory considerations to facilitate the merger process.

The parties announced the deal, which aims to expand Abbott’s portfolio in diagnostic testing and precision medicine. Weil’s role focuses on navigating competition laws and coordinating with antitrust authorities to address potential concerns and help secure clearance.

Abbott emphasized the significance of the transaction for advancing diagnostic capabilities and patient outcomes, while Exact Sciences highlighted the strategic fit with its portfolio and long-term growth potential. The transaction is subject to customary closing conditions and regulatory approvals.

The engagement underscores Weil’s experience in handling large-scale healthcare and life sciences mergers, including interactions with federal and state competition agencies, and its ability to counsel on complex merger matters that impact product markets, competitive dynamics, and innovation.

For further updates, stakeholders should monitor regulatory developments and official announcements from Abbott, Exact Sciences, and Weil.

Weil — 2025-12-05

More News